ImmuPharma plc (LON:IMM – Get Free Report) shares traded up 4.9% on Friday . The stock traded as high as GBX 4.70 ($0.06) and last traded at GBX 3.67 ($0.04). 109,382,164 shares were traded during trading, an increase of 245% from the average session volume of 31,664,631 shares. The stock had previously closed at GBX 3.50 ($0.04).
ImmuPharma Price Performance
The stock has a market capitalization of £15.30 million, a price-to-earnings ratio of -367.30 and a beta of 1.53. The stock’s 50 day simple moving average is GBX 1.44 and its 200-day simple moving average is GBX 1.65.
ImmuPharma Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Featured Stories
- Five stocks we like better than ImmuPharma
- How to Invest in Insurance Companies: A Guide
- ServiceTitan Made Waves in Its IPO, But Is the Stock a Buy?
- 3 Fintech Stocks With Good 2021 Prospects
- Netflix: Is This the Perfect Time to Buy a Streaming Powerhouse?
- Using the MarketBeat Stock Split Calculator
- Goldman Sachs Unveils 3 Massive Opportunities for 2025 Investors
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
